- Home
- OPBK vs ENLV Comparison
OPBK vs ENLV Comparison
Compare OPBK & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPBK | ENLV |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.5M | 249.3M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OPBK | ENLV |
|---|---|---|
| Price | $13.42 | $1.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $16.50 | $13.00 |
| AVG Volume (30 Days) | 23.3K | ★ 305.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $3,261,000.00 | N/A |
| Revenue This Year | $16.07 | N/A |
| Revenue Next Year | $11.60 | N/A |
| P/E Ratio | $10.74 | ★ N/A |
| Revenue Growth | ★ 53.60 | N/A |
| 52 Week Low | $10.43 | $0.66 |
| 52 Week High | $15.27 | $2.10 |
Technical Indicators
Market Signals| Indicator | OPBK | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 56.28 |
| Support Level | $13.13 | $1.00 |
| Resistance Level | $14.10 | $1.23 |
| Average True Range (ATR) | 0.38 | 0.07 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 40.78 | 58.00 |
Price Performance
Historical ComparisonAbout OPBK OP Bancorp
OP Bancorp is engaged in the general commercial banking business in Los Angeles, Orange, and Santa Clara Counties, California, Carrollton, Texas, and Las Vegas, Nevada. The Bank is focused on serving the banking needs of small- and medium-sized businesses, professionals, and residents with a particular emphasis on Korean and other ethnic minority communities. It operates with eleven full branches.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.